- +971 50 312 9316
- info@menovivreclinic.com
- Mon-Fri: 8AM - 7PM | Sun: 8AM - 4PM
Peptide therapy is one of the most rapidly developing areas of clinical medicine. These short chains of amino acids function as biological messengers, influencing metabolic function, tissue repair, hormonal signalling, immune response, and cognitive performance. Used correctly under proper medical supervision, they represent a meaningful clinical tool. Used carelessly outside a structured framework, they carry real risks.
In a therapeutic context, peptides may be used to stimulate or modulate the body’s own hormonal and metabolic processes, support tissue repair, reduce inflammatory signalling, influence neurotransmitter pathways, regulate immune function, and support skin and connective tissue regeneration.
The majority of peptide therapies currently in clinical use are prescribed off-label, meaning they are used outside their originally approved indications based on emerging clinical evidence. At Menovivre, every patient receives informed consent that explicitly discloses the off-label nature of their therapy before treatment begins.
Menovivre prescribes across seven therapeutic categories. All are compounded, prescription-only preparations sourced through Fusion Apothecary. No peptide is prescribed without a full medical assessment.
All peptides listed are off-label therapies. Prescribing is conducted under Menovivre’s clinical governance policy by certified physicians only.
Growth hormone secretagogues
(CJC-1295, Ipamorelin, Sermorelin)
Stimulate physiological, pulsatile growth hormone release. Supported by published research on body composition, recovery, and sleep architecture.
BPC-157
Multiple published studies support anti-inflammatory and tissue repair properties.
Thymosin Alpha-1
Published clinical research across immune modulation and infection response.
GHK-Cu
This is where Menovivre differs most from clinics that treat peptides as wellness products. There is no prescription without a thorough clinical evaluation first.
All peptides are sourced exclusively through Fusion Apothecary, a compounding pharmacy operating to pharmaceutical-grade standards. Every batch comes with sterility certification, batch traceability documentation, cold-chain logistics maintained at 2 to 8 degrees Celsius, aseptic handling protocols, and full regulatory documentation in compliance with UAE and DHA standards. These are compounded, prescription-only preparations. They are not the peptide supplements sold online or in health shops.
Peptide therapy is not appropriate for everyone. Absolute exclusion criteria include active or recent malignancy, pregnancy or breastfeeding, severe psychiatric illness, hormone-sensitive tumours, and uncontrolled metabolic or cardiovascular disease.
Enhanced screening and limited treatment duration apply to Dihexa (due to potent neurological activity), Kisspeptin-10 (due to hormonal axis influence), and PT-141 (due to cardiovascular and CNS effects). We do not prescribe to vulnerable populations, and we do not prescribe for cosmetic optimisation as a standalone indication.
Results depend on the specific peptide, your individual biology, baseline health, lifestyle, and the clinical indication being addressed. No outcome guarantees are made.
Many patients explore peptide therapy alongside existing hormonal protocols. If you are considering or currently on Hormone Replacement Therapy, your clinician will review any proposed peptide protocol in the context of your existing treatment. Our programmes may also provide a useful framework alongside individual peptide protocols.
Prescribing restricted to Dr Nirusha Kumaran and Dr Tasnim Elghandy, both holding valid certification in peptide therapy
Quarterly clinical audit of outcomes, adverse events, and adherence
Documented discontinuation criteria for every active protocol
An active adverse event registry and clinical KPI tracking
No prescribing in cases of active malignancy, pregnancy, or severe psychiatric illness
This level of institutional rigour is what separates physician-led peptide therapy from the commercially driven, under-regulated alternatives that exist elsewhere in the market.
Peptide therapy is a serious clinical undertaking. If you have a clear indication and want to explore whether it is appropriate for you, we are here to assess that thoroughly and honestly.
All peptide therapies are prescribed following consultation with a certified Menovivre physician.
Q: Are peptide therapies legal in the UAE?
Q: How are medical-grade compounded peptides different from peptide supplements?
Q: Are peptides the same as steroids or growth hormone injections?
A: No. Growth hormone secretagogues such as Ipamorelin and Sermorelin stimulate your pituitary gland to produce its own growth hormone in a physiological, pulsatile pattern. This is fundamentally different from injecting synthetic HGH or anabolic steroids, with a considerably different risk profile.
Q: Can I combine peptide therapy with HRT?
Q: How long does peptide therapy take to produce results?
A: It varies by peptide and individual. BPC-157 may produce effects on inflammation within weeks. Growth hormone secretagogues typically require three to six months for meaningful body composition changes. Cognitive peptides often produce earlier, subtler shifts. Realistic timelines are set at consultation and reviewed at every monitoring appointment.
Q: What happens if I experience a side effect?
A: Menovivre has an active adverse event protocol. Contact the clinic directly and our team responds within a defined clinical timeframe. Doses are adjusted, therapy is paused, or discontinued entirely where indicated.
Q: Can anyone book a consultation for peptide therapy?
A: Yes, anyone can book a consultation. However, a consultation does not guarantee a prescription. Eligibility is determined through clinical assessment, baseline labs, and risk stratification. If peptide therapy is not appropriate for you, we will tell you clearly and discuss alternatives.
